AI-powered breath testing designed to identify early signs of asthma attacks up to three days before symptoms worsen, non-invasively, and in under a minute.
Patients Evaluated in Clinical Feasibility Studies
Breath Parameters
Early Warning
Patents/Publications Accepted
Breath Predict combines clinical expertise with advanced breath analysis to support earlier insight, better monitoring, and more proactive asthma care – from clinic to home.
Our AI-powered breath platform analyses breath biomarker patterns associated with asthma deterioration, helping identify potential asthma attacks up to 3 days in advance, non-invasively and in under 1 minute.
Exhale-Dx® detects asthma with a promising accuracy using AI-powered breath analysis meaning no blood, no lab, no waiting.
Our deep learning framework predicts asthma attacks in advance, giving patients the time to act before an attack occurs.
Continuous monitoring from GP clinic to home dramatically reduces asthma attacks through early intervention and personalised care.
Four simple steps. Results in under 60 seconds.
The patient exhales into the Exhale-Dx device. No needles, no blood, no lab required. Completely non-invasive.
The device captures breath biomarkers across 13 distinct parameters from the exhaled sample in real time.
Our deep learning AI framework processes the breath data, detecting asthma patterns and calculating attack probability.
Results delivered in under 1 minute. Clinicians and patients receive actionable insights before an attack occurs.
The platform enables continuous respiratory monitoring from clinic to home, supporting proactive and preventive asthma care.
Proven in published clinical trials across adults and children
Diagnostic Accuracy
Advance Attack Prediction
Reduction in Asthma Attacks
Breath Parameters Analysed
Breath Predict is progressing Exhale-Dx through recognised regulatory pathways in the UK, Europe and the United States.
UK regulatory pathway for in-vitro diagnostic and medical device conformity.
European regulatory pathway under the In Vitro Diagnostic Regulation framework.
US regulatory pathway for diagnostic device submission and review.
Built by clinicians and AI researchers, Breath Predict is advancing the future of respiratory care through AI-powered breath analysis and clinical collaboration.
Our team is here to answer your questions about our technology, clinical research, and partnerships.
Breath Predict is a UK respiratory health technology company built by clinicians and AI researchers, developing AI-powered breath testing that helps predict asthma attacks before they happen.
Exhale-Dx is Breath Predict’s non-invasive, AI-powered breath testing platform. It analyses breath biomarker patterns associated with asthma and respiratory deterioration.
The patient simply exhales into the Exhale-Dx device. It captures 13 breath parameters in real time and our deep learning framework analyses them, delivering results in under 1 minute.
We work with NHS organisations, research partners and industry on clinical studies, pilots and pathway integration. Contact our team to discuss collaboration opportunities.
Asthma attacks are often detected too late. Breath Predict aims to identify early signs of deterioration up to 3 days in advance, so patients and clinicians can act before an attack occurs.
